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Inhibition of glycolysis using 2-deoxy-D-glucose (2DG, 20 mM, 24–48 h) combined with inhibition of the
pentose cycle using dehydroepiandrosterone (DHEA, 300 mM, 24–48 h) increased clonogenic cell killing
in both human prostate (PC-3 and DU145) and human breast (MDA-MB231) cancer cells via a mechanism
involving thiol-mediated oxidative stress. Surprisingly, when 2DGþDHEA treatment was combined with
an inhibitor of glutathione (GSH) synthesis (L-buthionine sulfoximine; BSO, 1 mM) that depleted
GSH490% of control, no further increase in cell killing was observed during 48 h exposures. In contrast,
when an inhibitor of thioredoxin reductase (TrxR) activity (Auranoﬁn; Au, 1 mM), was combined with
2DGþDHEA or DHEA-alone for 24 h, clonogenic cell killing was signiﬁcantly increased in all three human
cancer cell lines. Furthermore, enhanced clonogenic cell killing seen with the combination of DHEAþAu
was nearly completely inhibited using the thiol antioxidant, N-acetylcysteine (NAC, 20 mM). Redox
Western blot analysis of PC-3 cells also supported the conclusion that thioredoxin-1 (Trx-1) oxidation
was enhanced by treatment DHEAþAu and inhibited by NAC. Importantly, normal human mammary
epithelial cells (HMEC) were not as sensitive to 2DG, DHEA, and Au combinations as their cancer cell
counterparts (MDA-MB-231). Overall, these results support the hypothesis that inhibition of glycolysis
and pentose cycle activity, combined with inhibition of Trx metabolism, may provide a promising
strategy for selectively sensitizing human cancer cells to oxidative stress-induced cell killing.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Cancer cells, relative to normal cells, demonstrate up regulation
of glucose metabolism and a loss of regulation between glycolysis
and aerobic respiration [1–3]. Growing evidence supports the
hypothesis that tumor cells have altered mitochondrial metabo-
lism leading to increased steady-state levels of intracellular re-
active oxygen species (ROS) including superoxide (O2) and hy-
drogen peroxide (H2O2) [4–10]. It has also been hypothesized that
cancer cells compensate for increases in steady-state levels of ROSB.V. This is an open access article
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itz).by increasing glycolysis and pentose cycle activity to provide re-
ducing equivalents for hydroperoxide metabolism (Fig. 1) [4–9].
Glucose provides electrons for hydroperoxide metabolism via the
activity of the pentose cycle to regenerate nicotinamide adenine
dinucleotide phosphate (NADPH) to serve as the electron donor for
glutathione (GSH) and thioredoxin (Trx) dependent peroxidase
activity as well as through glycolysis to form pyruvate that can
directly react to detoxify hydroperoxides through a decarboxyla-
tion reaction (Fig. 1) [8,11,12].
Consistent with the hypothesis that cancer cells have increased
glycolysis and pentose cycle activity as a mechanism of protection
against increased ﬂuxes of hydroperoxides, inhibition of these
pathways through glucose deprivation is known to cause selective
oxidative stress and cytotoxicity in cancer cells versus normal cells
[9,13,14]. The glucose analog, 2-deoxyglucose, inhibits glycolysis
and cannot be fully oxidized in the pentose cycle, regenerating
only half as much NADPH as a molecule of glucose [15]. Previous
studies have demonstrated that 2DG treatment disrupts the
NADPþ/NADPH balance [16,17], is cytotoxic to tumor cells in vitrounder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. The pathways involving glucose and hydroperoxide metabolism believed to be involved with protection of cancer cells from metabolic oxidative stress (inhibitors of
Trx and GSH metabolism are shown in italics). 2DG competes with glucose for uptake into the cells competitively inhibiting pyruvate production and the pentose cycle after
glucose-6-phosphate-dehydrogenase (G6PD). DHEA inhibits G6PD. The GSH and Trx dependent systems participate in the detoxiﬁcation of H2O2 and organic hydroper-
oxides. NADPH is a source of reducing equivalents for the Trx/GSH-dependent systems. BSO inhibits glutamate cysteine ligase (γ-GCL) preventing glutathione synthesis.
Auranoﬁn is the inhibitor of thioredoxin reductase (TrxR), which reduces the oxidized Trx to the reduced form. These inhibitors were used alone and in combination to
increase the cancer cell oxidative stress, resulting in cancer cell cytotoxicity.
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that kill cancer cells via an oxidative stress mechanism in vivo
[16,20,21].
Glucose-6-phosphate dehydrogenase (G6PDH) is the rate lim-
iting enzyme in the oxidation of glucose through the pentose
phosphate pathway. G6PDH catalyzes the chemical reaction of D-
glucose-6-phosphate to 6-phospho-D-glucono-lactone regenerat-
ing NADPH (Fig. 1) [22]. Studies have shown that G6PDH expres-
sion and activity is increased in tumor tissues compared with
normal cells [23,24] and is strongly related to cellular oxidative
stress responses [25]. Dehydroepiandrosterone (DHEA) is an en-
dogenous primate steroid precursor that has been shown to be an
inhibitor of mammalian G6PDH [26,27]. It has been shown that
treatment with DHEA leads to a 30–40% decrease of
NADPH/NADPþ ratio, which may compromise cellular hydroper-
oxide metabolism [26].
GSH and Trx are cellular thiol redox cofactors that participate in
redox sensitive signaling pathways, scavenging hydroperoxides
and allowing for the maintenance of cellular redox potential.
Studies have demonstrated that these antioxidant systems are up
regulated in multiple cancer types compared to matched non-
cancerous tissue [28–32]. In this regard up-regulation of GSH and
Trx metabolism in breast and prostate cancer is correlated with
disease progression and poor patient outcomes [29,32]. The rate
limiting step in GSH synthesis is glutamate cysteine ligase, which
is inhibited by buthionine sulfoximine (Fig. 1; BSO). Trx is main-
tained in the reduced state by thioredoxin reductase (Fig. 1; TrxR).
Auranoﬁn (Au; Fig. 1) is a potent inhibitor of both cytosolic and
mitochondrial TrxR [33,34]. We have previously demonstrated
that simultaneous inhibition of the GSH and Trx pathways results
in cancer cell death via metabolic oxidative stress [35–37].
To determine drug combinations that were less toxic to normal
versus cancerous human cells that could selectively cause meta-
bolic oxidative stress induced cell-killing in cancer cells, the cur-
rent study focused on combining pharmacological agents that in-
hibit glycolysis and the pentose cycle (2-DG and DHEA) with in-
hibitors of thiol-dependent hydroperoxide metabolism (BSO and
Au). Treatment of human prostate and breast cancer cells with
either 2DG or DHEA was found to decrease clonogenic cell survival
and cell killing was further enhanced by combining both agents.
Although this decrease in cancer cell survival was associated with
disruptions in GSH metabolism, depleting GSH using BSO did not
further enhance clonogenic cell killing. In contrast, inhibiting Trxmetabolism using Au resulted in signiﬁcantly increased clonogenic
cell death when combined with DHEA or 2DGþDHEA that was
reversed using NAC a small molecule thiol antioxidant. Im-
portantly, normal human mammary epithelial cells (HMEC) were
not as sensitive to 2DG, DHEA, and Au induced cell killing as their
cancer cell counterparts (MDA-MB-231). These results support the
hypothesis that cancer cells are more dependent on glucose as
well as hydroperoxide metabolism than are normal cells and that
combining inhibitors of glycolysis and the pentose cycle with Au
may represent a promising approach for selectively causing oxi-
dative stress-induced cell killing in breast and prostate cancer
cells.Results
DHEA inhibits G-6-PDH activity and enhances 2DG cell killing in
breast and prostate cancer cells
We have previously determined that 2DG inhibits cancer cell
growth through an oxidative stress mechanism in multiple cancer
cell lines including MDA-MB231 breast cancer cells [20,35,37–39].
To test the hypothesis that an inhibitor of G6PDH could further
enhance metabolic oxidative stress caused by 2DG (Fig. 1) MDA-
MB231 breast cancer cells, PC-3 and DU145 prostate cancer cells
were treated with 2DG and/or DHEA for 24 and 48 h followed by
clonogenic cell survival assay (Fig. 2). DHEA inhibits the activity of
human recombinant G6PDH with an IC50 of 330 mM in vitro [27].
In the current studies 300 mM DHEA signiﬁcantly inhibited G6PDH
activity 35–50%, in all three of the cancer cell lines (Table 1).
20 mM 2DG was used to ensure that a relevant ratio of 2DG to
glucose (E1.8) was used to competitively inhibit glucose meta-
bolism in the cells grown in RPMI 1640 medium, which contains
11 mM glucose. As expected, treatment with 2DG or DHEA de-
creased surviving fractions of all 3 cell lines by 10–20% or 20–40%
after 24 or 48 h, respectively (Fig. 2A–C). Interestingly, treating the
cells with DHEA in combination with 2DG signiﬁcantly inhibited
clonogenic cell survival compared to treatment with 2DG or DHEA
alone, at both 24 and 48 h, in all three cancer cell lines tested
(Fig. 2A–C). These results support the hypothesis that simulta-
neous disruption of glucose metabolism using both a glycolysis
inhibitor (2DG) and an inhibitor of the pentose cycle (DHEA) en-
hanced cancer cell killing.
Fig. 2. Clonogenic cell survival curves for PC-3 cells (A), DU145 cells (B), and MDA-
MB-231 cells (C) treated with 2DG, DHEA, and BSO. 500,000–1,000,000 Cells were
plated in 60 mm dishes. After 24 h cells were treated with 20 mM 2DG, 300 mM
DHEA, and 1 mM BSO. Cells were collected for clonogenic survival assay at the 24,
and 48 h after the treatment started. Each measurement represents mean71 SD
from two experiments. *po0.001 difference versus control treatment, #po0.001
difference versus 2DG or DHEA treatment alone. One-way ANOVA was used with
Tukey's post-hoc analysis was used to test for statistical signiﬁcance.
Table 1
G-6-PDH activity (mU/mg) on the PC-3, DU145, and MD-MB231 cells treated with
300 mM DHEA for 24 h.
Cell line G-6-PDH activity on
vehicle control (mU/
mg)
G-6-PDH activity on
DHEA treatment (mU/
mg)
% Inhibition
PC-3 81.776.0 53.4710.8 34.6
DU145 222.3720.4 114.572.0 48.5
MDA-MB231 66.372.6 40.174.6 39.5
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killing
The GSH/glutathione disulﬁde (GSSG) redox couple is an
abundant thiol redox buffer in the cell and the ratio of GSH toGSSG is considered a good indicator of intracellular redox status as
well as providing a source of reducing equivalents that protects
cells from oxidative stress. GSH levels were examined in the 3 cell
lines, 24 and 48 h after treatment with 2DG and DHEA (Fig. 3).
Glutathione levels varied from 5 to 10 nmol/mg of protein in these
cancer cell lines. Treatment with 2DG caused total GSH and GSSG
levels to rise at 24 h and/or 48 h, in all 3 cell lines (Fig. 3A and B).
DHEA treatment alone only increased GSH and GSSG levels in PC-3
cells at 48 h. As seen with 2DG alone, DHEA combined with 2DG
treatment signiﬁcantly increased total GSH and GSSG by 48 h in all
3 cell lines except for GSSG in DU145 cells. As expected following
1 mM BSO treatment, total GSH decreased to r10% of control
(Fig. 3A). Furthermore GSSG was non-detectable in all cell lines
treated with BSO (data not shown). Surprisingly, adding 1 mM BSO
to the combination of 2DG and DHEA did not signiﬁcantly enhance
clonogenic cell killing in any of the 3 cell lines tested at 24 or 48 h
(Fig. 2A–C). These results indicate that drug treatment causes
disruptions to GSH metabolism. However depletion of GSH does
not enhance clonogenic cell killing, suggesting that if drug treat-
ment was mechanistically related to thiol-disruptions, total GSH
content was not the critical factor determining toxicity.
Disrupting Trx metabolism with Au potentiates 2DG and DHEA cancer
cell killing
Trx provides the reducing equivalents for the metabolism of
hydroperoxides by peroxiredoxins (Prx) that plays an important
role in protecting cells from oxidative stress that complements the
GSH-dependent metabolism of hydroperoxides by glutathione
peroxidases (GPx) (Fig. 1). When PC-3 and MB-231cells were
treated with 1 mM Au for 24 h, TrxR activity was inhibited by 50–
80% (Po0.05, N¼3) compromising the ability of Trx and Prx
metabolism to scavenge hydroperoxides in cancer cells. Treating
PC-3 and MDA-MB231 cells with 1 mM Au for 24 h decreased
clonogenic survival by 30% while having no effect on DU145
cells (Fig. 4A–C). Combining Au with 2DG or with 2DGþDHEA
signiﬁcantly increased cytotoxicity in all 3 cell lines compared to
2DG or 2DGþDHEA treatments, respectively (Fig. 4A–C). Inter-
estingly, Au combined with DHEA treatment also signiﬁcantly in-
creased clonogenic cell death in all three cancer cell lines com-
pared to either drug treatment alone (Fig. 4A–C). These results
support the hypothesis that Trx-mediated metabolism of hydro-
peroxides is relatively more important than GSH metabolism to
protecting these cancer cells from oxidative stress induced by in-
hibition of glucose metabolism and the pentose cycle.
NAC protects cancer cells from clonogenic cell killing mediated by
DHEA and Au
NAC is a nonspeciﬁc thiol antioxidant that has been shown to
inhibit metabolic oxidative stress [14,35,37]. In the current study,
NAC (20 mM for 24 h) signiﬁcantly inhibited clonogenic cell killing
in MDA-MB-231 and PC-3 cells treated with Au or the combination
Fig. 3. Effect of 2DG, DHEA and BSO treatment on glutathione levels in PC-3, DU145, and MDA-MB-231 cells. 1,000,000 Cells were plated into 100 mm dishes and after 24 h
treated with 20 mM 2DG, 300 mM DHEA, and 1 mM BSO. At the end of 24 and 48 h total glutathione (A) and glutathione disulﬁde (GSSG) (B) were measured using
spectrophotometric recycling assay. One way ANOVA with least signiﬁcant difference (LSD) post-hoc analysis was performed resulting in *Po0.05, compared to control at
the same time point.
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isms by which NAC could act as a protective agent, redox Western
blots investigating oxidation of cytoplasmic Trx-1 were performed
(Fig. 5C and D). The results showed that DHEAþAu treatment
caused signiﬁcant Trx-1 oxidation in PC-3 cells that was inhibited
by NAC (Fig. 5C and D). These data support the hypothesis that
cancer cells treated with DHEAþAu have increased oxidation of
intracellular thiols that is inhibited by treatment with NAC.Au, 2DG, and DHEA demonstrate differential cell killing in normal
versus cancer breast epithelial cells
To investigate whether these drug combinations were selectively
toxic to MDA-MB-231 (human breast cancer) versus HMEC cells
(normal human untransformed breast epithelial), exponentially
growing cultures were exposed to combinations of 20 mM 2DG and
300 mM DHEA for 18 h followed by 1 mM Au for 15 min prior to
Fig. 4. Au treatment enhances cancer cell killing from 2DG and DHEA treatment in
PC-3 (A), DU145 (B), and MDA-MB-231 (C) cells. Cells were plated in 60 mm dishes
and treated with 2DG and DHEA as before with the addition of 1 mM Au for 24 h
after which clonogenic cell survivals assay was performed. One-way ANOVA was
used with Tukey's post-hoc analysis resulted in *po0.001 differences versus
control, #po0.01 versus all other experimental conditions without Au.
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2DGþDHEAþAu treatment groups were found to be signiﬁcantly
more cytotoxic to MDA-MB-231 cells, relative to HMEC cells (Fig. 6).
These results demonstrate that drug treatments targeting inhibition
of glycolysis and pentose cycle activity, combined with inhibition of
thioredoxin metabolism are selectively cytotoxic to human breast
cancer cells versus normal breast epithelial cells.
Discussion
Cancer cells appear to have up regulated glycolytic metabolism
and demonstrate some alterations aerobic respiration [1–3].A possible consequence of this altered cancer cell metabolism is
disruptions in mitochondrial electron transport chain activity
which could result in increased one-electron reductions of O2 to
form superoxide (O2), which can undergo dismutation reactions
to become H2O2[8,9,40,41]. Glucose metabolism via the pentose
phosphate pathway leads to the regeneration of NADPH and the
formation of pyruvate which have been shown to function in the
cellular peroxide detoxiﬁcation pathways [8,9,42,43]. Both the
GSH and the Trx pathways which use cysteine thiol-disulﬁde ex-
change reactions in the detoxiﬁcation of H2O2 and other hydro-
peroxides, use NADPH for a co-factor to regenerate the reduced
thiol (Fig. 1). These observations have led to the proposal that
tumor cells increase their glucose utilization to form NADPH and
pyruvate to compensate for the increased production of ROS (i.e.,
O2 and H2O2), which may be produced from abnormal mi-
tochondrial electron transport chain activity [8,9]. In support of
this idea it has been demonstrated that changes in G6PDH activity,
which is responsible for the regeneration of NADPH by the pentose
cycle, can alter steady-state levels of intracellular ROS [25]. This
suggests that inhibiting pentose cycle metabolism and peroxide
detoxiﬁcation pathways could preferentially kill cancer cells via
metabolic oxidative stress. Consistent with this hypothesis, studies
have shown that inhibiting glycolysis either through glucose de-
privation or with 2DG preferentially induces increased cytotoxicity
and oxidative stress in transformed versus non-transformed cells
[8,9,14]. Interestingly, the clinically relevant inhibitor of glycolysis,
2DG, was found to cause less severe cancer cell cytotoxicity (re-
lative to glucose deprivation), presumably because 2DG can only
partially inhibit the pentose cycle since it is still a substrate for
G6PD [9,15].
Based on this background information, the current study as-
sessed cancer versus normal cell toxicity associated with si-
multaneous inhibition of glucose metabolism in both glycolysis
and the pentose cycle as well as the relative importance of GSH-
versus Trx-dependent peroxide metabolic pathways in the re-
sulting cell killing seen in human breast and prostate cancer cells.
2DG, DHEA, BSO and Au were chosen because they are well tol-
erated drugs in humans and they have the ability to inhibit the
glucose and/or hydroperoxide metabolism, as shown in Fig. 1.
The combination of 2DG and DHEA appeared to cause at least
additive cytotoxicity, as well as signiﬁcant increases in total GSH
and GSSG in all cancer cells tested. Surprisingly, BSO treatment
depleted GSH levels but did not enhance 2DGþDHEA toxicity,
suggesting that, while thiol metabolism appeared disrupted, GSH
itself was not directly involved in the cytotoxic mechanism of the
drug combination. It was thought that other thiol redox systems
could be compensating for this stress and/or be more directly in-
volved in the cytotoxicity induced by 2DGþDHEA treatment.
Therefore, Trx metabolism was investigated for the role it might
play in 2DG and DHEA induced cytotoxicity.
The antirheumatic agent, Au at a dose which inhibited TrxR
activity by approximately 50–80%, resulted in a decrease in clo-
nogenic survival of PC-3 and MB231 cells but not DU145 cells. Au
treatment also enhanced the cytotoxicity of 2DG in all 3 cell lines.
Most interesting was the signiﬁcant decrease in clonogenic sur-
viving fraction seen in all cancer cells when Au was combined with
DHEA treatment. This increased toxicity correlated with increased
Trx-1 oxidation status, suggesting that disruption to Trx metabo-
lism was casually related to the cytotoxic mechanism of the drug
combination. This hypothesis was further supported by the evi-
dence that NAC treatment was able to protect against cytotoxicity
as well as inhibit increases in the oxidation of Trx-1 seen with
DHEAþAu. Furthermore, Au treatment alone or in combination
with 2DG and/or DHEA caused increased clonogenic cell killing in
cancer cells (MDA-MB-231) versus normal cells (HMEC). These
results support the hypothesis that these drug combinations might
Fig. 5. NAC rescues cancer cells from the cytotoxicity induced by combined DHEA and Au. Cells were plated and treated as above with the addition of 20 mM NAC for 24 h to
select dishes followed by the clonogenic survival assay for PC-3 (A) and MB231 (B). Results were normalized to control and error bars represent mean71SD from two
different experiment treatment dishes. Each treatment dish was then plated into at least three cloning dishes each. One-way ANOVA with Tukey's post-hoc analysis resulted
in *po0.001 versus control, #po0.01 versus treatment without NAC. After 24 h treatment, PC-3 cells were also harvested for redox western blotting for oxidized and
reduced Trx-1 as described in methods (N¼4) (C). DTT and H2O2 were added during the ﬁnal 10 min of incubation as positive and negative controls but were not included in
the quantitative analysis (C). Quantiﬁcation of the treatment groups included in the immuno-blot was performed using ImageJ (N¼4) (D). One-way ANOVA followed by the
LSD post-hoc analysis was used to test for statistical signiﬁcance (*po0.05).
Fig. 6. Effect of 2DG, DHEA and Au on normal breast HMEC cells versus breast
cancer MDA-MB-231 cells. Cells were plated and 24 h later treated with 20 mM
2DG and 300 mM DHEA for 17–18 h. 1 mM Au was added 15 min before cells were
collected for clonogenic assay. One-way ANOVA was used with Tukey's post-hoc
analysis resulted in *po0.001 when MD-MB231 cells are compared with the same
treatment groups in HMEC cells.
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apeutic advantage for use as an adjuvant therapy.
DHEA is an endogenous hormone produced by the adrenal
glands that is present in young male athletes at approximately0.18 mM [44] and decreases from that peak level with age. DHEA
supplementation has been investigated for many age related ill-
nesses. Doses of up to 200 mg/day have been given to large groups
of subject for up to a year with very few side effects however
supplementation results in at most a 25 fold increase in DHEA
levels which is still lower than the 300 mM dose needed for G6PD
inhibition [45]. There is active research looking for more potent,
less androgenic DHEA analogs [46–48] and non-steroid G6PD in-
hibitors for cancer treatment [27]. Au is a gold phosphine that has
been used safely in humans as an anti-rheumatoid arthritis drug
for three decades and is an excellent inhibitor of both cytosolic and
mitochondrial TrxR with an IC50 of 5–20 nM [33,34]. Arthritis
patients are typically given a dose of 6 mg/day orally which results
in steady state serum level of 0.44–2.8 mM [49,50] which is within
the range needed for TrxR inhibition. It has been reported that Trx-
1 levels are increased in several human tumors, and that higher
Trx-1 levels are associated with more aggressive tumor growth
[28,29,31]. We and others have shown that Au has antitumor ac-
tivity, both in vitro and in vivo when combined with agents that
increase oxidative stress [36,51–53]. This paper is the ﬁrst to show
that Au combined with a G6PD inhibitor results in signiﬁcant
enhancement of metabolic oxidative stress in cancer cells. These
results also support the hypothesis that simultaneous inhibition of
glycolysis and the pentose cycle [59] is selectively cytotoxic to
prostate and breast cancer cells by a pathway that can be further
enhanced by inhibition of Trx metabolism. These results support
L. Li et al. / Redox Biology 4 (2015) 127–135 133the speculation that combined modality cancer therapies designed
to increase metabolic oxidative stress and cancer cell killing by
inhibiting the pentose cycle as well as Trx-mediated hydroper-
oxide metabolism may provide a useful adjuvant for the treatment
of prostate and breast cancer.Materials and methods
Cells and culture conditions
All the cancer cell lines were obtained from American Type
Culture Collection (Manassas, MA). Human prostate cancer cell
lines PC-3 and DU145, and human breast cancer cell line MDA-
MB231 were maintained in RPMI-1640 medium from Mediatech,
Inc. (Herndon, VA, USA) with 10% fetal bovine serum (FBS, Hy-
clone, Logan, Utah). Stock cultures were maintained in 5% CO2 and
21% O2 in a humidiﬁed 37 °C incubator in the absence of anti-
biotics. Normal non-immortalized human mammary epithelial
cells (HMEC) were purchased from Lonza (Walkersville, MD) and
the cells were maintained in MEBM media (Lonza), and were
cultured per vendor's instructions.
Drug treatment
2DG, DHEA, BSO, and NAC were obtained from Sigma Chemical
Co. (St. Louis, MO). Au was obtained from Axxora, LLC (San Diego,
CA). A ﬁnal concentration of 20 mM 2DG, 300 mM DHEA, 1 mM
BSO, and/or 1 mM Au were added to cells cultures in exponential
growth. A stock solution of 1 M 2DG and 20 mM BSO was dis-
solved in phosphate-buffered saline (PBS), and 0.5 M DHEA were
dissolved in DMSO. 1 mM Au was dissolved in 100% ethanol. NAC
was dissolved in 1 M sodium bicarbonate (pH 7.0) immediately
prior to use. 2DG, DHEA, BSO, and NAC solutions were sterile ﬁl-
tered prior to addition to cell cultures and the required volume
added directly to the media to achieve a ﬁnal concentration as
mentioned above.
Clonogenic assays
Cells were plated in 60-mm tissue culture dishes at densities to
assure exponential growth for 24 h at which time 2DG, DHEA, BSO
and/or Au were added as speciﬁed in the legend of each ﬁgure.
Following treatment cells were trypsinized, counted and plated for
clonogenic cell survival assay. Brieﬂy, cells were diluted and plated
at low densities, 200–2000 cells, in 60 mm dishes in complete
media with antibiotics (gentamycin, 50 mg/L), and allowed to
grow for 14 days. Surviving colonies were ﬁxed with 70% ethanol
and stained with G250 Coomassie Blue and counted (450 cell
colonies were considered survivors). The surviving fraction was
deﬁned as the number of colonies counted divided by the number
of cells plated. The normalized surviving fraction was deﬁned as
surviving fraction of each dish divided by the average surviving
fraction from sham treated controls with at least 3 cloning dishes
per condition, repeated in at least 3 separate experiments (unless
otherwise noted in legend).
GSH/GSSG assay
Following treatment, cells were scraped and harvested in ice-
cold PBS and centrifuged at 4 °C. The supernatant was discarded,
and the cell pellets were frozen at 20 °C prior to biochemical
analysis. Pellets were thawed and homogenized in 50 mM po-
tassium phosphate buffer, pH 7.8, containing 1.34 mM DETAPAC.
Total glutathione content was determined by the method of An-
derson [54]. The yellow color of 5-thio-2-nitrobenzoic acid (TNB)generated from GSH and DTNB was detected at 412 nm. The rate at
which color accumulates is proportional to the amount of total
glutathione. Reduced and oxidized glutathione were distinguished
by the addition of 2 ml 2-VP mixed 1:1 (v:v) with ethanol per 30 ml
of sample followed by incubation for 1 h and assayed as described
by Grifﬁth [55]. Glutathione levels were normalized to the protein
content using the method of Lowry et al. [56].
G6PDH activity assay
The activity of glucose 6-phosphate dehydrogenase was mea-
sured by the method of Glock & McLean with minor modiﬁcations
[57]. Immediately prior to the assay, DETAPAC buffer was added to
the cell pellet and the mixture was sonicated at low power. The
reaction was started by adding 12 mM 6 Phosphogluconic Acid
(6PGA), 12 mM glucose-6-phosphate for the combined substrates
to 2 mM NADPþ solution and incubating at 37 °C for 2 min.
Samples were added to the reaction solutions and the spectro-
photometric activity was measured for 5 min at 340 nm. The
G6PDH activity is calculated by subtracting the absorbance for
6PGA alone from the combined substrate.
Thioredoxin reductase assay
Enzymatic activity of thioredoxin reductase was determined by
subtracting the time dependent increase in absorbance at 412 nm
in the presence of the TrxR activity inhibitor, aurothioglucose from
total activity, using the assay kit provided Sigma Chemical Co. (St.
Louis, MO). One unit of activity was deﬁned as 1 mM TNB formed/
min mg protein.
Thioredoxin redox western
Trx-1 redox Western blots were done as described [58]. Brieﬂy,
after 24 h treatment, cells were harvested by scraping directly into
G-Lysis buffer containing 50 mM of sodium iodoacetate (IAA, Sig-
ma I9148) pH 8.3, for a positive control for Trx-1 oxidation and
reduction, 2 mM DTT and 2 mM H2O2 were added to some plates,
incubated at 37 °C for 10 min prior to incubating with IAA. After
incubating with IAA at 37 °C for 30 min, excess IAA was removed
using desalting MicroSpin G-25 columns (GE Healthcare, Bio-Sci-
ences Corp., Piscataway, NJ) [58]. Protein concentration was then
determined using Bio-Rad protein assay dye reagent. 55 mg of
protein were loaded onto a 15% Ready-Gel (Bio-Rad). Gels were
electroblotted to a nitrocellulose membrane and probed for Trx-1
using an anti-Trx-1 primary antibody (American Diagnostica,
Greenwich, CT) and horseradish peroxidase-conjugated anti-goat
IgG secondary antibody, followed by chemiluminescent detection
(SuperSignal West Pico, Pierce) with X-ray ﬁlm. Band integrated
densities were determined using imageJ software as described
[37].
Statistical analysis
Statistical analysis was done using GraphPad Prism version
4 for Windows (GraphPad Software, San Diego, CA). To determine
differences between 3 or more means, one-way ANOVA with Tu-
key's post-hoc analysis were performed. Error bars represent the
standard error of the mean. All statistical analysis was performed
at the Po0.05 level of signiﬁcance.
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